categoryMenu_new
 
  Home
  EXTRAORDINARY AH Teaching from Spiritual Hierarchy
  AbundantHope
  NEW READERS! Read Here First
  Supporting AH
  Leadership of AbundantHope
  Announcements
  Regional AH Sites
  Other Sites with AH material
  Contact Us
  Becoming A Messiah
  OUR PUBLIC FORUM IS OPEN TOO ALL
  Mission Ideas
  System Busting
  Cleric Letter/English
  Translations of Cleric Letter
  AH Member Writings
  Candace
  Ron
  Rosie
  Jess
  Brian's Poetry
  James
  Giuseppe
  Esteban
  Telepathic Messages
  Candace
  Jess Anthony
  Vince
  Leonette
  John
  Adam
  Bela
  Joyce
  Hazel
  Kibo
  Peter
  Rosie
  Johan
  Lucia
  Lucia G
  Rubens
  Shellee-Kim
  Ben
  Dorothea
  Solon
  Others
  Targeted Messages
  Hano
  Light Flower
  Changing The Face Of Religion
  - Phoenix Journals - PDF in German
  Candace on Religion
  Other Spiritual Pieces
  Spiritual Nuggets by the Masters
  Phoenix Journals
  Phoenix Journals - PDF
  Telepathic Messages PDF books
  Selections from the Urantia Book
  Illustrations For The Urantia Book
  CMGSN Pieces
  THE WAVE
  Environment/Science
  David Crayford and the ITC
 
  Health and Nutrition
  Podcasts, Radio Shows, Video by AH
  Political Information
  True US History
  Human/Animal Rights
  The Miracle That Is Me
  Education
  Resources
  911 Material
  Books - eBooks
  government email/phone #'s
  Self Reliance
  Video
  Websites
  Alternative News Sources
  Art and Music
  Foreign Sites
  Health and Healing
  Human/Animal Rights
  Scientific
  Spiritual
  Vegan Recipes
  Translated Material
  Dutch
  Gekanaliseerde berichten Jess
  Gekanaliseerde berichten Candace
  Gekanaliseerde berichten Anderen
  Artikelen/berichten
  French
  Canal Jess
  Par Candace
  Other Channels
  Articles
  German
  Telepathische Nachrichten (Candace)
  Telepathische Nachrichten (Jess)
  Telepathische Nachrichten (div.)
  AH Mitgliederbeiträge (Candace)
  AH Mitgliederbeiträge (Jess)
  Spirituelle Schätze
  Italian
  Translations - Candace
  Translations - Jess
  Translations - Others
  Portuguese
  by Candace
  By Jess
  By Others
  Spanish
  Anfitriones Divinos
  Bitácoras Fénix
  Creadores-de-Alas (WingMakers/Lyricus)
  Escritos de Candace
  Escritos de Otros
  Monjoronsón
  Telemensajes de Candace
  Telemensajes de Jess Anthony
  Telemensajes de Otros
  Chinese
  By Candace
  By Jess
  By Others
  Korean Translations
  Hungarian Translations
  Swedish Translations

Search
[an error occurred while processing this directive]
Health and Nutrition Last Updated: Nov 26, 2020 - 10:10:25 PM


‘Average’ Effectiveness & Unexplained Side Effects: 7 QUESTIONS that AstraZeneca Needs To Answer About its Covid-19 Vaccine
By Russia Today
Nov 26, 2020 - 10:03:23 PM

Email this article
 Printer friendly page Share/Bookmark

https://www.rt.com/news/507829-astrazeneca-covid-vaccine-questions/

25 Nov, 2020
Get short URL

‘Average' effectiveness & unexplained side effects: 7 QUESTIONS that AstraZeneca needs to answer about its Covid-19 vaccineFILE PHOTO. ©  Reuters / Dado Ruvic


The drug manufacturer AstraZeneca said on Monday it would seek emergency authorization for its coronavirus vaccine with various regulators. However, it might first have to answer a number of serious questions about its jab.

The British-Swedish company, which has developed its candidate vaccine together with the University of Oxford, "will begin the submission of the clinical data to regulators around the world that have a framework in place for emergency use or conditional approval," its spokesman said on Monday, adding that the list of the regulators that will receive the application particularly includes the US Food and Drug Administration (FDA).

ALSO ON RT.COMAstraZeneca's Covid-19 vaccine shows average efficacy of 70%

The statement came as the drug manufacturer published interim results of the vaccine's clinical trials, which it said "showed the vaccine was highly effective in preventing COVID-19" and declaring its overall effectiveness to amount to 70 percent - much lower than 90-percent efficacy that other leading vaccine candidates showed.

Yet, some information published by the company appeared to be quite puzzling, while some data seemed to be lacking.

AstraZeneca might eventually find itself in need of answering key questions about its would-be jab as it rushed to get regulators' approval for it.

1.Half dose or full dose ?

The company's assessment of its vaccine effectiveness in fact comes as an estimated average for two slightly different tests. AstraZeneca admitted in its Monday release that a group of volunteers initially got a half-dose jab, followed by afull one a month later. Another, larger, group got two full doses.

The first regimen showed 90-percent efficacy, although such results were based on analysis of slightly more than 2,700 volunteers. The second one, which involved almost 8,900 people, showed only a 62-percent efficacy.

READ MORE Commercial interests & Russia/West geopolitical struggle combine to make race for Covid-19 vaccines a new battleground

Commercial interests & Russia/West geopolitical struggle combine to make race for Covid-19 vaccines a new battleground

Such a discrepancy shows that AstraZeneca has two approaches to its vaccine use, demonstrating quite different results, and that it may probably need to file for approval of each one separately.

Which one would it choose, if any? How long will the new clinical trials take, as results from these will be needed for any dose changes? Or will it stick to its "average" assessment approach?

2.Admitting mistakes ?

The half-dose shots administered to a group of volunteers were, in fact, the result ofa mistake, Mene Pangalos, head of AstraZeneca's non-oncology research and development, admitted to Reuters. Yet, this mistake went virtually unnoticed until the researchers started evaluating side-effects after the first dose.

Still, the company decided to just press on with the trials and simply to administer the second dose to those who received only half of the first one. Such an approach may be problematic with some regulators, such as the FDA, according to some analysts.

"I don't believe that the FDA will look positively at any trial where the dose, or the age cohorts, or any other variable were changed mid-trial, inadvertently or deliberately," Geoffrey Porges, an SVB Leerink analyst, said.

If, as Mene Pangalos says, it was a mistake, when and how did this mistake occur? Would AstraZeneca check up on its clinical trial results once again to make sure no other mistakes had creeped into its research?

3.Solving a puzzle ?

One of the most perplexing statements made by AstraZeneca is that its half-dose approach seemingly proved to be more effective than the full-dose one. After all, it was the half-dose group results that showed the vaccine's 90-percent efficacy.

A larger dosage usually produces a stronger immune response, so such results made many experts wonder. Still, the vaccine developers apparently cannot explainthe results either, at least for now.

Sarah Gilbert, an Oxford University professor of vaccinology that co-developed the vaccine together with specialists from AstraZeneca, told Bloomberg she was "surprised" by such results, adding that she was not sure if the company had the "full answer," and citing the need to "look into it some more."

So, would it be reasonable for AstraZeneca to seek the vaccine's approval at a time when it is not sure why the jab works the way it works?

4.Concealing facts ?

A report by Bloomberg suggested, citing Moncef Slaou, the head of the US Operation Warp Speed program, that the supposedly highly-effective half-dose regimen was administered to participants in a younger group that were no older than 55 years-old. The full-dose test, in turn, included elderly people.

ALSO ON RT.COMPuzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

Yet, AstraZeneca says nothing of this in its press release, although such details could be crucial for understanding how a vaccine works, as well as for assessing its real effectiveness. The company's silence in this instance raises a number of questions.

Why did it not disclose those facts, if they are true? Why did it not refute them, if they are false? Were there any other differences between the participants of the trials when it comes to demography or any other characteristics, such as their states of health?

5.Not enough evidence ?

Results presented by AstraZeneca were based on data received from just over 11,000 participants - roughly a half of the 23,000 included in the trials. As for its supposedly highly effective half-dose regimen, it was administered to fewer than 3,000 volunteers.

Such numbers might not be enough for Phase-Three vaccine trials to be considered successful.

Apart from that, the company only mentioned that it had recorded a total of 131 Covid-19 cases among the participants, without disclosing whether anyone of those who did receive the vaccine in any dosage had contracted the disease.

READ MORE AstraZeneca's Covid-19 vaccine trial ON HOLD after adverse reaction of UK participant - report

AstraZeneca's Covid-19 vaccine trial ON HOLD after adverse reaction of UK participant - report

Will AstraZeneca disclose additional data and possibly start new clinical trials specifically to prove the effectiveness of its half-dose regimen? The company has not yet announced any such plans.

6.Unexplained side effects ?

AstraZeneca's clinical trials have previously been briefly suspended in the UK over reports about two cases of possible autoimmune diseases linked to them. At least one of the participants was reported to have developed a serious spinal inflammatory disorder called transverse myelitis.

The person in question later reportedly recovered and the trials were resumed. However, the company has not yet provided any solid explanation for those incidents. Whether such information would be made public is still an open question.

7.Evading responsibility ?

What AstraZeneca did, though, was to secure full indemnity from all damages in most countries that struck vaccine-supply deals with the company. Such agreements were reached in July, well before the somewhat puzzling test data arrived.

"This is a unique situation where we as a company simply cannot take risk if in ..four years the vaccine is showing side effects," Ruud Dobber, a member of Astra's senior executive team, told Reuters.

Would the drug manufacturer change its stance now and agree to share some legal risks in case any damage would emanate from its own mistakes during the clinical trials? This is particularly concerning, as there is no long-term study to date of the safety of chimpanzee adenovirus vector vaccine.

When will its long-term effects be studied and presented to the public ?

ALSO ON RT.COMRace for Covid-19 cure: Boom Bust explores why EU has a problem with Russia's cheap and effective vaccine

Think your friends would be interested ? Share this story !





All writings by members of AbundantHope are copyrighted by
©2005-2020 AbundantHope - All rights reserved

Detailed explanation of AbundantHope's Copyrights are found here


Top of Page

Health and Nutrition
Latest Headlines
Dr. Anthony Fauci Fails to Rule Out Double Masking for Those Who Are Vaccinated
Miraculous anti-racist Covid-19 Strain Resurfaces in Australia, Just In Time For Indigenous Protests
53 Dead in Gibraltar in 10 Days After Experimental Pfizer mRNA COVID Injections Started
Joe Biden Hints Coronavirus Restrictions Through ‘Early Fall’ — ‘Never Said I’d Do It in Two Months’
Ministers For Health Are Front and Center in The Ongoing COVID Tyranny
Can You Believe This? A Real Medical Breakthrough in An Era Of Fake News!
Lockdowns Cost 4 Times More Jobs than 2009 Financial Crisis, Worse Than The Great Depression
Medical Doctor Warns that “Bacterial Pneumonias Are on the Rise” from Mask Wearing
British legislator calls for widespread vitamin D rollout following 82% reduction in COVID-19 deaths in Spain
Don’t Hug Your Grandchildren Even After Vaccine, Warns UK Health Expert
Lockdowns Are Betraying An Entire Generation: 500,000 More UK Kids Face Mental Health Issues
Fauci: Mandatory Vaccines, Vaccine Passports ? “Anything Is Possible”
Boris Says It’s ‘Too Early’ to Say If Lockdown Will End by Spring
Majority Of Americans Already Wear A Mask In Public
Lockdown Extremism: An Obsession for the Insane and the Fascists
Halfway Through This Winter of Covid, Overall Mortality is Around Normal For This Time of Year. Something doesn’t add up
A Warning for the Vaccine-Hesitant
Lockdown Having No Impact on Coronavirus Rates in England, Vaccine Will Have 'limited impact' in Short Term - Infectious disease expert
Thousands of Israelis Test POSITIVE for Covid-19 Despite Receiving Pfizer/BioNTech Jab
‘More died than in all of WW2 !’ Biden Wants All Americans Masked Up & Travelers Quarantined, Predicts 500,000 Covid deaths by Feb